| Literature DB >> 33082079 |
Marius M Hoeper1, Christine Pausch2, Ekkehard Grünig3, Hans Klose4, Gerd Staehler5, Doerte Huscher6, David Pittrow7, Karen M Olsson8, Carmine Dario Vizza9, Henning Gall10, Nicola Benjamin3, Oliver Distler11, Christian Opitz12, J Simon R Gibbs13, Marion Delcroix14, H Ardeschir Ghofrani15, Stephan Rosenkranz16, Ralf Ewert17, Harald Kaemmerer18, Tobias J Lange19, Hans-Joachim Kabitz20, Dirk Skowasch21, Andris Skride22, Elena Jureviciene23, Egle Paleviciute23, Skaidrius Miliauskas24, Martin Claussen25, Juergen Behr26, Katrin Milger27, Michael Halank28, Heinrike Wilkens29, Hubert Wirtz30, Elena Pfeuffer-Jovic31, Lars Harbaum4, Werner Scholtz32, Daniel Dumitrescu32, Leonhard Bruch33, Gerry Coghlan34, Claus Neurohr35, Iraklis Tsangaris36, Matthias Gorenflo37, Laura Scelsi38, Anton Vonk-Noordegraaf39, Silvia Ulrich40, Matthias Held32.
Abstract
The term idiopathic pulmonary arterial hypertension (IPAH) is used to categorize patients with pre-capillary pulmonary hypertension of unknown origin. There is considerable variability in the clinical presentation of these patients. Using data from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension, we performed a cluster analysis of 841 patients with IPAH based on age, sex, diffusion capacity of the lung for carbon monoxide (DLCO; <45% vs ≥45% predicted), smoking status, and presence of comorbidities (obesity, hypertension, coronary heart disease, and diabetes mellitus). A hierarchical agglomerative clustering algorithm was performed using Ward's minimum variance method. The clusters were analyzed in terms of baseline characteristics; survival; and response to pulmonary arterial hypertension (PAH) therapy, expressed as changes from baseline to follow-up in functional class, 6-minute walking distance, cardiac biomarkers, and risk. Three clusters were identified: Cluster 1 (n = 106; 12.6%): median age 45 years, 76% females, no comorbidities, mostly never smokers, DLCO ≥45%; Cluster 2 (n = 301; 35.8%): median age 75 years, 98% females, frequent comorbidities, no smoking history, DLCO mostly ≥45%; and Cluster 3 (n = 434; 51.6%): median age 72 years, 72% males, frequent comorbidities, history of smoking, and low DLCO. Patients in Cluster 1 had a better response to PAH treatment than patients in the 2 other clusters. Survival over 5 years was 84.6% in Cluster 1, 59.2% in Cluster 2, and 42.2% in Cluster 3 (unadjusted p < 0.001 for comparison between all groups). The population of patients diagnosed with IPAH is heterogenous. This cluster analysis identified distinct phenotypes, which differed in clinical presentation, response to therapy, and survival.Entities:
Keywords: cluster; mortality; phenotypes; pulmonary arterial hypertension; survival
Year: 2020 PMID: 33082079 DOI: 10.1016/j.healun.2020.09.011
Source DB: PubMed Journal: J Heart Lung Transplant ISSN: 1053-2498 Impact factor: 10.247